Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)

NCT03003416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2019-03-14

No results posted yet for this study

Summary

This study will evaluate the efficacy of Ozurdex® as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).

Conditions

Interventions

DRUG

dexamethasone intravitreal implant

Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Nathalie Mesnard · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2018-12-19
Completion
2018-12-19

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03003416 on ClinicalTrials.gov